Featured Research

from universities, journals, and other organizations

Toward Prevention Of A Common Complication Of Cataract Surgery

Date:
August 15, 2007
Source:
American Chemical Society
Summary:
A newly developed method for coating the intraocular lenses used in millions of cataract surgery procedures may prevent a common complication of cataract surgery, according to a new report. Such surgery corrects the vision loss that occurs when the lens of the eye becomes clouded.

A cataract is a clouding of the lens in the eye that affects vision. Most cataracts occur in older persons. By age 80, more than half of all people in the United States either have a cataract or have had cataract surgery.
Credit: Courtesy of NIH/National Eye Institute

A newly developed method for coating the intraocular lenses (IOLs) used in millions of cataract surgery procedures may prevent a common complication of cataract surgery, according to a new report. Such surgery corrects the vision loss that occurs when the lens of the eye becomes clouded.

Christine Jιrτme and colleagues report development of a method for applying a polyethylene glycol coating to IOLs. In laboratory experiments, researchers showed that the coating reduced accumulation of the protein film and adhesion of cells responsible for formation of secondary cataracts.

The coating did not affect the optical properties of the lens. It also could be applied to certain other surfaces in order to discourage undesirable protein accumulation and adhesion of cells, the report states.

During the operation, a small incision in the front of the lens capsular bag is used to remove the clouded crystalline lens. The IOL is inserted into the empty capsular bag. Researchers noted that IOL replacement surgery is a safe and well-established procedure to correct the vision loss from a cataract. In about 25 percent of cases, however, the back portion of the capsule eventually becomes clouded with a "secondary" cataract. Jιrτme notes that treatment is available for secondary cataracts, but describes it as risky.

The article "Improved Performances of Intraocular Lenses by Poly(ethylene glycol) Chemical Coatings" is scheduled for the Aug. 13 issue of ACS' Biomacromolecules.


Story Source:

The above story is based on materials provided by American Chemical Society. Note: Materials may be edited for content and length.


Cite This Page:

American Chemical Society. "Toward Prevention Of A Common Complication Of Cataract Surgery." ScienceDaily. ScienceDaily, 15 August 2007. <www.sciencedaily.com/releases/2007/08/070813102442.htm>.
American Chemical Society. (2007, August 15). Toward Prevention Of A Common Complication Of Cataract Surgery. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2007/08/070813102442.htm
American Chemical Society. "Toward Prevention Of A Common Complication Of Cataract Surgery." ScienceDaily. www.sciencedaily.com/releases/2007/08/070813102442.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins